Some news on lung cancer treatments from the European Society for Medical Oncology (or ESMO):
- A new immunotherapy (atezolizumab or Tecentriq) improved survival vs chemo as second-line therapy for patients with NSCLC. This drug could be FDA-approved by October 19.
- Pembrolizumab (Keytruda) improved survival vs chemo as first-line therapy in patients with NSCLC if they had high levels of the biomarker PD-L1. Pembrolizumab is already approved as second-line therapy (for NSCLC), but could be FDA-approved as first-line therapy by December 24.